149 related articles for article (PubMed ID: 34848243)
21. Janus nanocarrier-based co-delivery of doxorubicin and berberine weakens chemotherapy-exacerbated hepatocellular carcinoma recurrence.
Zhang F; Jia Y; Zheng X; Shao D; Zhao Y; Wang Z; Dawulieti J; Liu W; Sun M; Sun W; Pan Y; Cui L; Wang Y; He K; Zhang M; Li J; Dong WF; Chen L
Acta Biomater; 2019 Dec; 100():352-364. PubMed ID: 31563690
[TBL] [Abstract][Full Text] [Related]
22. Bifunctional Aptamer-Doxorubicin Conjugate Crosses the Blood-Brain Barrier and Selectively Delivers Its Payload to EpCAM-Positive Tumor Cells.
Macdonald J; Denoyer D; Henri J; Jamieson A; Burvenich IJG; Pouliot N; Shigdar S
Nucleic Acid Ther; 2020 Apr; 30(2):117-128. PubMed ID: 32027209
[TBL] [Abstract][Full Text] [Related]
23. Targeted delivery of doxorubicin through CD44 aptamer to cancer cells.
Natesh J; Chandola C; Meeran SM; Neerathilingam M
Ther Deliv; 2021 Oct; 12(10):693-703. PubMed ID: 34592836
[No Abstract] [Full Text] [Related]
24. Identification of microRNAs specific for epithelial cell adhesion molecule-positive tumor cells in hepatocellular carcinoma.
Ji J; Zheng X; Forgues M; Yamashita T; Wauthier EL; Reid LM; Wen X; Song Y; Wei JS; Khan J; Thorgeirsson SS; Wang XW
Hepatology; 2015 Sep; 62(3):829-40. PubMed ID: 25953724
[TBL] [Abstract][Full Text] [Related]
25. miR-26b-5p helps in EpCAM+cancer stem cells maintenance via HSC71/HSPA8 and augments malignant features in HCC.
Khosla R; Hemati H; Rastogi A; Ramakrishna G; Sarin SK; Trehanpati N
Liver Int; 2019 Sep; 39(9):1692-1703. PubMed ID: 31276277
[TBL] [Abstract][Full Text] [Related]
26. Osteopontin regulates epithelial mesenchymal transition-associated growth of hepatocellular cancer in a mouse xenograft model.
Bhattacharya SD; Mi Z; Kim VM; Guo H; Talbot LJ; Kuo PC
Ann Surg; 2012 Feb; 255(2):319-25. PubMed ID: 22241292
[TBL] [Abstract][Full Text] [Related]
27. Enhanced doxorubicin delivery to hepatocellular carcinoma cells via CD147 antibody-conjugated immunoliposomes.
Wang J; Wu Z; Pan G; Ni J; Xie F; Jiang B; Wei L; Gao J; Zhou W
Nanomedicine; 2018 Aug; 14(6):1949-1961. PubMed ID: 29045824
[TBL] [Abstract][Full Text] [Related]
28.
Diril M; Özdokur KV; Yıldırım Y; Karasulu HY
Pharm Dev Technol; 2023 Dec; 28(10):915-927. PubMed ID: 37921920
[TBL] [Abstract][Full Text] [Related]
29. Selection and Characterization of a Novel DNA Aptamer, Apt-07S Specific to Hepatocellular Carcinoma Cells.
Yu XX; Ge KL; Liu N; Zhang JY; Xue ML; Ge YL
Drug Des Devel Ther; 2020; 14():1535-1545. PubMed ID: 32368012
[TBL] [Abstract][Full Text] [Related]
30. Isoginkgetin synergizes with doxorubicin for robust co-delivery to induce autophagic cell death in hepatocellular carcinoma.
Wang Y; Yi Y; Yao J; Wan H; Yu M; Ge L; Zeng X; Wu M; Mei L
Acta Biomater; 2022 Nov; 153():518-528. PubMed ID: 36152910
[TBL] [Abstract][Full Text] [Related]
31. Aptamer-conjugated and doxorubicin-loaded unimolecular micelles for targeted therapy of prostate cancer.
Xu W; Siddiqui IA; Nihal M; Pilla S; Rosenthal K; Mukhtar H; Gong S
Biomaterials; 2013 Jul; 34(21):5244-53. PubMed ID: 23582862
[TBL] [Abstract][Full Text] [Related]
32. An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells.
Zhao N; You J; Zeng Z; Li C; Zu Y
Small; 2013 Oct; 9(20):3477-84. PubMed ID: 23609964
[TBL] [Abstract][Full Text] [Related]
33. EpCAM-positive hepatocellular carcinoma cells are tumor-initiating cells with stem/progenitor cell features.
Yamashita T; Ji J; Budhu A; Forgues M; Yang W; Wang HY; Jia H; Ye Q; Qin LX; Wauthier E; Reid LM; Minato H; Honda M; Kaneko S; Tang ZY; Wang XW
Gastroenterology; 2009 Mar; 136(3):1012-24. PubMed ID: 19150350
[TBL] [Abstract][Full Text] [Related]
34. Proliferating EpCAM-Positive Ductal Cells in the Inflamed Liver Give Rise to Hepatocellular Carcinoma.
Matsumoto T; Takai A; Eso Y; Kinoshita K; Manabe T; Seno H; Chiba T; Marusawa H
Cancer Res; 2017 Nov; 77(22):6131-6143. PubMed ID: 28951464
[TBL] [Abstract][Full Text] [Related]
35. Aptamer-drug conjugate: targeted delivery of doxorubicin in a HER3 aptamer-functionalized liposomal delivery system reduces cardiotoxicity.
Dou XQ; Wang H; Zhang J; Wang F; Xu GL; Xu CC; Xu HH; Xiang SS; Fu J; Song HF
Int J Nanomedicine; 2018; 13():763-776. PubMed ID: 29440899
[TBL] [Abstract][Full Text] [Related]
36. Aptamer-mediated gene therapy enhanced antitumor activity against human hepatocellular carcinoma in vitro and in vivo.
Xiao S; Liu Z; Deng R; Li C; Fu S; Chen G; Zhang X; Ke F; Ke S; Yu X; Wang S; Zhong Z
J Control Release; 2017 Jul; 258():130-145. PubMed ID: 28522194
[TBL] [Abstract][Full Text] [Related]
37. Androgen Receptor Enhances the Efficacy of Sorafenib Against Hepatocellular Carcinoma Through Enriched EpCAM Stemness.
Lai HC; Chung WM; Chang CM; Liao PY; Su YT; Yeh CC; Jeng LB; Ma WL; Chang WC
Anticancer Res; 2020 Mar; 40(3):1285-1295. PubMed ID: 32132025
[TBL] [Abstract][Full Text] [Related]
38. EpCAM, a new marker for cancer stem cells in hepatocellular carcinoma.
Terris B; Cavard C; Perret C
J Hepatol; 2010 Feb; 52(2):280-1. PubMed ID: 20006402
[TBL] [Abstract][Full Text] [Related]
39. A human anti-c-Met Fab fragment conjugated with doxorubicin as targeted chemotherapy for hepatocellular carcinoma.
Chen X; Ding G; Gao Q; Sun J; Zhang Q; Du L; Qiu Z; Wang C; Zheng F; Sun B; Ni J; Feng Z; Zhu J
PLoS One; 2013; 8(5):e63093. PubMed ID: 23675455
[TBL] [Abstract][Full Text] [Related]
40. Self-Assembled DNA-Protein Hybrid Nanospheres: Biocompatible Nano-Drug-Carriers for Targeted Cancer Therapy.
Lee D; Baek S; Kim YY; Bang Y; Jung HN; Im HJ; Song YK
ACS Appl Mater Interfaces; 2022 Aug; 14(33):37493-37503. PubMed ID: 35969502
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
